Literature DB >> 10516523

Das multifokale elektroretinogramm in der diagnostik und verlaufskontrolle lokalisierter Netzhautfunktionsstörungen: fallbericht eines patienten mit chorioretinopathia centralis serosa.

A M Palmowski1, E E Sutter, M A Bearse, W Fung.   

Abstract

The role of multifocal electroretinography (MF-ERG) in the diagnosis and follow-up of localized areas of retinal dysfunction is discussed. A 42-year-old male with the preliminary diagnosis of optic neuritis in his left eye was referred for evaluation with the MF-ERG. Simultaneous cone ERGs were obtained from 103 locations within the central 50 degrees of the retina. During an 8-month follow-up four MF-ERGs were obtained. Bilaterally reduced paracentral response amplitudes contradicted the preliminary diagnosis. Subsequently central serous chorioretinopathy was diagnosed. Follow-up showed normalization of the MF-ERG responses in the left eye while retinal function in the right eye showed initial worsening. The noninvasive MF-ERG lends itself to follow-up in patients with central serous chorioretinopathy.

Entities:  

Mesh:

Year:  1999        PMID: 10516523     DOI: 10.1159/000027448

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

1.  Clinical applications of multifocal electroretinography.

Authors:  U Kretschmann; M Bock; R Gockeln; E Zrenner
Journal:  Doc Ophthalmol       Date:  2000       Impact factor: 2.379

2.  Influence of dopamine deficiency in early Parkinson's disease on the slow stimulation multifocal-ERG.

Authors:  Anja M Palmowski-Wolfe; Maria Timoner Perez; Stefanie Behnke; Gerhard Fuss; Martin Martziniak; Klaus W Ruprecht
Journal:  Doc Ophthalmol       Date:  2006-06-22       Impact factor: 2.379

3.  Detection of retinal dysfunction in vitelliform macular dystrophy using the multifocal ERG (MF-ERG).

Authors:  Anja M Palmowski; Reiner Allgayer; Bernhild Heinemann-Vernaleken; Volker Scherer; Klaus W Ruprecht
Journal:  Doc Ophthalmol       Date:  2003-03       Impact factor: 2.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.